The Sigma-1 Bridge

A neuron is an energy emergency in slow motion. It spends most of its ATP holding electrochemical gradients across its membranes — pumping sodium out, potassium in, calcium down — so that it can fire again. Interrupt that supply and the gradients decay within minutes.

Most of that ATP comes from oxidative phosphorylation inside mitochondria, which needs a steady stream of oxygen. A much smaller, faster supply comes from glycolysis in the cytosol, which can run without oxygen but yields far less per glucose.

This is the tension the whole story turns on. When oxygen falls, the efficient pathway falters and the cell must improvise. The question this documentary examines is whether a molecule — DMT — acting through the sigma-1 receptor at the ER–mitochondrial contact site, can help a stressed neuron hold on a little longer.

In the cytosol, one glucose is invested with two ATP, split into two three-carbon sugars, and harvested back for a net 2 ATP, 2 NADH and 2 pyruvate. No oxygen is consumed directly in these ten reactions.

But there is a catch built into step six: oxidising the sugar reduces NAD⁺ to NADH. Glycolysis can only keep running if that NAD⁺ is regenerated. In oxygen, the mitochondrion does this. In hypoxia, the cell must find another way — a point that will matter enormously later.

Each pyruvate is then carried into the mitochondrial matrix through the mitochondrial pyruvate carrier, where pyruvate dehydrogenase converts it to acetyl-CoA, releasing CO₂ and reducing another NAD⁺ to NADH. That acetyl-CoA is the fuel the Krebs cycle burns next.

Inside the matrix, each acetyl-CoA is fed into a cycle that strips it of electrons. Per acetyl-CoA the cycle yields 3 NADH, 1 FADH₂, 1 GTP/ATP and 2 CO₂. The NADH and FADH₂ are the real prize: energetic carriers that will drive the electron transport chain.

Three enzymes here are switched up by calcium — and this is the hinge of the entire DMT hypothesis. When mitochondrial calcium rises into a controlled range, it accelerates exactly these reactions, matching fuel oxidation to demand.

Zoom out from the matrix and something striking appears: the mitochondrion sits pressed against the endoplasmic reticulum. At these junctions — the mitochondria-associated ER membraneMAMMitochondria-associated ER membrane — the nanometre-scale contact site where the endoplasmic reticulum presses against the mitochondrion without fusing., or MAM — the two organelles come within nanometres of each other but do not fuse.

This narrow gap is not empty. A molecular machine spans it. The IP₃ receptor in the ER membrane is tethered by GRP75GRP75A chaperone (mortalin) that physically tethers the IP₃ receptor on the ER to VDAC1 on the mitochondrion, aligning the calcium hand-off. to VDAC1VDAC1Voltage-dependent anion channel 1 — the main pore in the outer mitochondrial membrane through which calcium (and metabolites) pass. in the outer mitochondrial membrane, which lines up with the MCUMCUMitochondrial calcium uniporter — the inner-membrane channel that imports calcium into the matrix. in the inner membrane. This is the calcium conduit between the two organelles.

The sigma-1 receptorsigma-1 receptorAn ER-resident chaperone protein (not a classical surface receptor) that senses cellular stress and regulates calcium signalling and ion channels. is not a conventional surface receptor. It is an ER-resident chaperone that sits at the MAM and senses the cell's state. In the resting condition it is held in a complex with another chaperone, BiP/GRP78, and ER calcium is relatively stable.

When the cell is stressed — or when a sigma-1 ligand binds — the receptor changes conformation and dissociates from BiP. Freed, it helps stabilise IP₃-receptor signalling at the contact site, supporting a controlled pulse of calcium into the mitochondrion rather than a disorganised flood.

Toggle the state on the diagram: watch BiP release and a measured calcium pulse begin. This regulation of calcium and cell survival is the receptor's established job — the part of the story that does not depend on DMT at all.

DMT is a small indole molecule — structurally a cousin of serotonin — and it is endogenous: mammalian tissue can make it. Among its targets is the sigma-1 receptor, where it acts as a ligand, engaging the very chaperone we have just met at the MAM.

When DMT binds, it can drive the same conformational shift that stress does: BiP releases, and sigma-1 is positioned to influence IP₃-receptor calcium signalling. That is the entry point for the whole hypothesis that follows.

Now turn the oxygen down. Because oxygen is the final electron acceptor at Complex IV, its scarcity is felt right along the chain. Electrons cannot be offloaded, so the carriers stay reduced — NADH accumulates relative to NAD⁺. Proton pumping weakens, the membrane potential sags, ATP synthase slows, and mitochondrial ATP output falls.

The cell responds. It leans harder on glycolysis, converts pyruvate to lactate to regenerate NAD⁺, and as ATP drops relative to AMP and ADP, AMPK switches on. Under low oxygen HIF-1α is stabilised, driving a glycolytic adaptation programme. During impaired electron flow — and especially on reoxygenation — reactive oxygen species can rise.

Under hypoxia the cell reorganises around its fastest oxygen-free option. Pyruvate is diverted to lactate — and this is not simply waste. Reducing pyruvate to lactate regenerates NAD⁺, which glycolysis needs in order to keep producing its small, oxygen-independent trickle of ATP.

At the same time, HIF-1α ramps up glycolytic machinery and induces PDK, which inhibits pyruvate dehydrogenase to keep pyruvate out of an oxygen-starved TCA cycle. The cell is actively conserving oxygen.

Here is the heart of the idea, drawn deliberately in dashed lines. If DMT engages sigma-1 at the MAM, it might steady the calcium hand-off to the mitochondrion — enough of a controlled pulse to nudge the calcium-sensitive dehydrogenases, improve NADH delivery, and make the most of whatever oxygen remains.

Notice what each link is made of. The first two are experimental. The middle links are established biology borrowed from outside the DMT–hypoxia experiment. The last three are inferences — reasonable, but not directly shown in this setting.

It is tempting to read the hypothesis as “calcium boosts energy, so more calcium is better.” The biology says otherwise. Calcium's effect is biphasic.

Drag the calcium control across its range. Too little, and the dehydrogenases are under-driven. A moderate pulse sits at the peak of the green curve — metabolism is optimised. Push further and the green curve falls while the red damage curve climbs: ROS, permeability transition, collapsing membrane potential.

This is precisely why regulation — not just calcium — is the proposed benefit of sigma-1. A controlled pulse lands near the peak; a disorganised flood overshoots into damage.

Here is the tension. The mechanism this whole documentary builds — sigma-1 steadying MAM calcium to optimise mitochondrial metabolism and survival — is slow. Chaperone reorganisation, metabolic flux and transcription play out over minutes to hours. A seconds-fast abort cannot be explained by it.

So what could act that fast? The same receptor offers a fast lane: sigma-1 directly and rapidly modulates voltage- and ligand-gated ion channels — and DMT inhibits neuronal Na⁺ channels through sigma-1. Add DMT's serotonergic actions (5-HT1B/1D, the triptan-like targets, and 5-HT2A) on trigeminovascular tone and brainstem gating, and you have plausible ways to break the trigeminal-autonomic reflex loop quickly.

Why does a story about DMT and hypoxia touch Alzheimer's disease at all? Because the same machinery is under scrutiny. Alzheimer's research increasingly examines disrupted mitochondrial metabolism, calcium homeostasis and ER–mitochondrial contact sites — the MAM we have been standing inside.

Sigma-1 receptor agonism is being investigated as a possible way to influence these systems. That is a reason for scientific interest in sigma-1 biology broadly. It is not evidence that DMT treats, prevents or reverses Alzheimer's disease.

Let us be exact about the edge of what is known. It is established that sigma-1 regulates MAM calcium signalling and survival, and that calcium activates the matrix dehydrogenases. It is experimental that DMT binds sigma-1 and improves survival of hypoxic human cells in a sigma-1-dependent way. Everything that stitches these into a single “DMT raises ATP via calcium” mechanism is still inference or hypothesis.